SpyGlass Pharma, Inc. (SGP) Key Metrics
SGP valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $802.8M
- Enterprise value
- $709.3M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 4.1
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- —
SGP key metrics, 2023–2025
Fiscal year ended December 31, 2025 · U.S. dollarsSGP returns How much profit the business earns on the capital it uses.
SGP per-share figures Results divided by the shares outstanding at year-end.
SGP financial health Debt, liquidity and how easily interest is covered.
SGP returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
SGP debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
SGP cash returned to shareholders
SGP key metrics
2023–2025| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Per share | |||
| Revenue per share | $0.00 | $0.00 | $0.00 |
| Earnings per share | −$1.25 | −$0.91 | −$0.42 |
| Operating cash flow per share | −$1.02 | −$0.69 | −$0.38 |
| Free cash flow per share | −$1.05 | −$0.75 | −$0.39 |
| Cash per share | $3.37 | $0.51 | $0.50 |
| Book value per share | −$3.10 | −$1.90 | −$1.03 |
| Tangible book value per share | −$3.10 | −$1.90 | −$1.03 |
| Capex per share | $0.02 | $0.06 | $0.01 |
| Debt per share | $0.05 | — | — |
| Shares outstanding | 31.9M | 31.9M | 31.9M |
| Change in shares outstanding | 0.0% | 0.0% | — |
| Returns & profitability | |||
| Return on assets (ROA) | −57.3% | −90.5% | −32.4% |
| Return on tangible assets | −34.4% | −125.1% | −32.4% |
| Financial health | |||
| Total debt | $1.6M | — | — |
| Cash & short-term investments | $107.4M | $16.3M | $15.8M |
| Net debt | −$105.9M | −$16.3M | −$15.8M |
| Debt / assets | 0.01 | — | — |
| Current ratio | 12.67 | 2.23 | 25.57 |
| Quick ratio | 12.67 | 2.23 | 25.57 |
| Working capital | $100.2M | $9.6M | $39.0M |
| Invested capital | −$204.7M | −$76.7M | −$48.8M |
| Tangible asset value | −$98.8M | −$60.5M | −$33.0M |
| Net current asset value | −$105.9M | −$66.4M | −$33.5M |
| Graham net-net per share | −$3.35 | −$2.12 | −$1.83 |
| Capital allocation | |||
| Share buybacks (net) | $1.4M | $0 | — |
| Capex / depreciation | 1.29 | 7.35 | 1.77 |
| Efficiency | |||
| Days payables outstanding | 1,393.8 | — | — |
| Receivables turnover | 0.00 | — | — |
| Payables turnover | 0.26 | — | — |
| Asset turnover | 0.00 | 0.00 | 0.00 |
| Average receivables | $431,000 | — | — |
| Average payables | $2.3M | $1.3M | $639,161 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% |
Computed from SGP's annual financial statements (latest annual report filed March 26, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
SGP valuation and financial ratios
It ended the year with $1.6 million of debt and $107.4 million in cash and short-term investments, a net cash position of $105.9 million. It returned $1.4 million to shareholders: $0 in dividends and $1.4 million in share buybacks.
See the SGP income statement, the SGP chart for price history, or the SGP stock overview for the latest quote and news.
SGP key metrics FAQ
How much debt does SpyGlass Pharma have?
SpyGlass Pharma had total debt of $1.6 million at the end of fiscal 2025 and more cash than debt.
Does SpyGlass Pharma buy back its shares?
Yes. SpyGlass Pharma spent $1.4 million on net share repurchases in fiscal 2025 Shares outstanding changed 0.0% over the year, to 31.9M..
What is SpyGlass Pharma's current ratio?
SpyGlass Pharma's current ratio was 12.67 at the end of fiscal 2025: current assets were 12.67 times current liabilities.